We are pleased to announce a funded PhD studentship opportunity at Newcastle University, as part of the MRC DiMeN-XL doctoral programme.
The project, titled Unlocking insights into skin cancer risk with laser-enabled skin analytics, will investigate an innovative approach to skin analysis using medical laser technology, molecular biology, proteomics and advanced imaging.
The research will explore how ablative fractional lasers can be used for minimally invasive skin sampling to investigate molecular markers associated with photoageing, DNA damage and skin carcinogenesis. The ultimate aim is to improve our understanding of skin cancer risk and inform future approaches to skin cancer prevention.
The successful candidate will join our research group and work with an interdisciplinary supervisory team spanning biomedical technology, molecular dermatology, skin cancer biology and proteomics. The studentship also includes a three-month industrial placement with Lynton Lasers, offering valuable experience in medical laser technology and its clinical applications.
Interested?
The studentship is funded for four years. For full project details, eligibility requirements and application instructions, please visit the PhD studentship advert on FindAPhD.
We look forward to hearing from prospective applicants!
Keng has been invited to speak at the Skin@Bath Skin & Synovium Network Symposium in December 2026. His talk will focus on our dual-domain, semi-dissolving and hydrogel-forming microneedle technologies.
The talk is scheduled for the second day of the symposium, 11 December 2026.
Over the last two years, our lab has developed three pharmaceutical technologies. At first glance, they might seem unrelated. But they all share a rather unexpected origin.
In this video podcast, Keng speaks with Dr Manveer Sandhu about how it all began with a single research challenge: developing a long-acting microneedle formulation.
The work required laboratory equipment that wasn’t readily available, so we decided to build our own. That decision set in motion a series of developments that eventually led to the three technologies we have today.
Watch the conversation below to discover how one research challenge led to three different pharmaceutical technologies.
Many thanks to Manveer for inviting us to share our story on his Signal over Noise podcast series.
Want to learn more? Visit our Publications section to explore the scientific papers behind these technologies.
Liang YM, Azizi J, Ng KW, Goh CF. Transdermal delivery and formulation design of opioids: Where are we now and where are we heading? J Control Release. 2026;394:114894. https://doi.org/10.1016/j.jconrel.2026.114894
This has been another excellent transnational collaboration with Dr Choon Fu Goh and colleagues. In this paper, we take a deep dive into a seemingly simple question with a deceptively complex answer: why is it so difficult to deliver opioid drugs across the skin?
Transdermal delivery offers clear advantages for opioid therapy, including more stable drug levels and improved patient convenience compared to oral or injectable routes. However, only a small number of opioids, such as fentanyl and buprenorphine, have been successfully developed into marketable patches. The main limitation is the skin itself. As a barrier, it is highly effective, and drugs require a very specific balance of properties, including molecular size, lipophilicity, and potency, to cross it. Many widely used opioids, including morphine, fall outside this narrow window.
In the review, we examine the main strategies that have been explored to address this challenge, including chemical permeation enhancers, formulation approaches, and physical methods. A consistent theme is that success in controlled laboratory settings does not always translate into clinical use. Improving permeation alone is not sufficient if the system cannot deliver clinically relevant doses reliably in practice. It increasingly appears that formulation strategies relying on passive diffusion across intact skin are unlikely to succeed. Looking ahead, active skin penetration strategies are likely to lead progress by enabling more consistent drug delivery while reducing dosing burden.
I thank my co-authors for their contributions to this work, and I hope the review will serve as a useful resource for the research community.
Ng KW, Archbold L, Lau WM. Building Otto: An open-source Franz diffusion cell autosampler for automating in vitro skin permeation studies. HardwareX. 2026;25:e00735. doi: 10.1016/j.ohx.2025.e00735
We have recently published a paper in HardwareX describing the design and construction of Otto, an open-source autosampler robot for Franz diffusion cell experiments. Otto is built using a desktop 3D printer as a gantry, a small number of custom 3D-printed parts, and commonly available laboratory consumables. It is designed to automate sampling and can collect up to 100 samples per run.
The system uses a Creality Ender 3 Pro 3D printer for motion control, with add-on components printed in-house on Prusa Research printers. The aim of the project was to develop a low-cost, accessible solution for automating repetitive sampling tasks in skin permeation studies, without reliance on proprietary hardware.
Otto has previously been validated. In a recent hydrogel study, Otto was used to collect every sample in a 72-hour skin permeation experiment, operating fully unattended throughout. The new HardwareX paper brings together the design rationale, build instructions and practical considerations needed for others to construct and use the system.
The paper, which is now available, provides a step-by-step guide to building Otto and is intended to support reproducibility and reuse by other laboratories. The 3D models and design files are openly available, and the models are also hosted on Printables.
Alongside the hardware, a companion application called OttoMate has been developed to generate the G-code used to control the system via a graphical user interface. The software is under active development and is available on GitHub.
A series of videos demonstrating different aspects of Otto’s operation, including assembly and sampling, is also available via a YouTube playlist.
This work was carried out by our team at Newcastle University, with contributions from Liam Archbold and Dr Wing Man Lau. Otto has been open-sourced in the hope that others will find it useful and adapt it for their own applications, and we are open to collaborations.
We would also like to acknowledge the EPSRC for funding this work.
We have open-sourced the design files for Otto, the Franz diffusion cell autosampler that we built to automate skin permeation studies. This means we’re sharing the 3D-printable models with the world, for free. Anyone may print, modify and share these files with others — with attribution. The files are released under the CC BY 4.0 licence.
Abdelghany TM, Vo N, Vukajlovic D, Smith E, Wong JZ, Jackson E, Hilkens CMU, Lau WM, Ng KW, Novakovic K. Engineering and in vitro evaluation of semi-dissolving, hydrogel-forming polymeric microneedles for sustained-release drug delivery. Int J Pharm. 2025:125932. https://doi.org/10.1016/j.ijpharm.2025.125932
In our latest paper, we describe a microneedle formulation that utilises two polymeric domains: a soluble one and an insoluble one. The insoluble domain is chemically crosslinked and traps the soluble polymer, along with the drug, within it. This combination creates a microneedle array patch that can release a drug for over 2 months.
It can contain a significantly larger dose than microneedles where the drug is contained within the microneedle tips only (e.g., detachable microneedles). The drug reservoir in the backplate makes this possible to support extended release. It uses one-pot synthesis, a mild hydroalcoholic solvent system and mild temperatures to aid manufacturability and drug stability.
For the first time, we were able to see, on video, how the microneedles released the drug and swell as they hydrated. These videos are buried in the supplementary files for the paper, but I thought it worthy of sharing more widely here:
In this collaborative paper—our second with the Malaysian team led by Dr Choon Fu Goh—we examine some commercially available cosmetic products and ask what lessons we can learn from them to enhance pharmaceutical microneedle product translation and commercialisation.
We have known, for a long time, that the regulatory hurdles for pharmaceutical products are much greater than those for cosmetic products. Still, it’s interesting to see how cosmetic microneedle products have surged years (if not decades) ahead of their pharmaceutical counterparts, particularly in the Asian market. A low regulatory hurdle could spur innovation, but it could equally grow fad. How can one tell which it is? We examined a selection of commercially available cosmetic microneedle products to find out, and report our findings in this paper.
This has been an interesting paper to work on. I have admired Goh’s tenacity collecting microneedle patches from pharmacies on his various international trips across Asia for this study. Last year, I hosted him in Newcastle to conduct parts of the study, including some microscopy work and the optical coherence tomography (OCT) analysis on microneedle penetration in ex vivo pig skin. It’s rewarding to see those efforts pay off.
Citation: Chan HKY, Archbold L, Lau WM, Ng KW. Validating Otto: a Franz diffusion cell autosampler to automate in vitro permeation studies, Journal of Pharmaceutical Sciences, 2025:103837. https://doi.org/10.1016/j.xphs.2025.103837
We have a new paper out. This one is close to my heart because I personally spent many hands-on hours developing Otto.
Who’s Otto?
Otto is a Franz diffusion cell (FDC) autosampler robot. It replaces manual sampling and refilling of FDCs in a skin (and cornea, mucosal membrane, etc.) permeation experiment. Those who have worked with FDCs before would know how fiddly, time-consuming and labour-intensive that is. It’s a job most suited for a robot.
But Otto is about more than us trying to avoid menial labour. It’s about the quality of the science, too.
Let me rephrase that — it’s primarily about the quality of the science.
For a long time, we have noted many skin drug absorption studies that include unusually large sampling gaps of ≥16 hours, presumably because the researchers were unable to collect samples outside normal working hours. This sampling gap could allow the drug to accumulate in the FDC receptor chamber and, consequently, underestimate drug absorption due to sink condition being violated. We have faced similar logistical challenges ourselves as local rules prevent some researchers from working out of normal working hours. A FDC autosampler would solve these challenges, but we have not been able to afford any of the few commercial FDC automation systems available. When COVID-19 hit, and lab access was further restricted, we finally found the impetus and time to build the FDC autosampler we had always needed, for less than £500, and retrofitted it to our existing FDCs.
Thus, Otto was born.
Otto is a Franz diffusion cell (FDC) autosampler robot, adapted from the Creality Ender 3 Pro 3D printer. This picture depicts an automated skin permeation experiment using FDCs, in which Otto handled FDC sampling and refilling fully unattended. See the full paper for details on the number labels. Image reproduced under the CC BY 4.0 licence.
We have spent the last 2 years validating Otto’s performance. In this paper, we demonstrate that the sampling gap indeed led to violation of sink condition and underestimation of drug absorption. We further show that Otto improved data quality by avoiding the sampling gap. We have benchmarked Otto’s precision and accuracy against a trained researcher. We are pleased to report that it outperforms the researcher on both counts.
Otto is better than the commercial offerings in many ways. It is built on open-source technologies, using inexpensive consumables and 3D-printed custom parts, and is therefore fully customisable. It has a small footprint of just 50 cm × 46 cm. It can be retrofitted to generic FDCs and can collect up to 100 samples per experiment, fully unattended. The samples are collected directly into high-performance liquid chromatography (HPLC) autosampler vials, so it integrates seamlessly with downstream analysis without any further liquid handling, nor modification to the FDCs or analytical equipment.
Logistical, human resource and financial constraints continue to grip many research organisations long after COVID-19 restrictions have ended. Otto should prove itself a valuable asset in many research labs seeking to retrofit an automation solution to their existing FDCs.
The build instructions for Otto are too extensive to include in this paper, so we will be publishing them separately.
We have been working with Professor Katarina Novakovic‘s team for several years now to develop long-acting microneedle patch formulations based on our ULTRA technology. ULTRA stands for Ultra-long and Tunable Release of Actives. It is a polymeric composite material that confers exceptional sustained release properties.
Our work in this area is yet unpublished, but it has already attracted the attention of RTS (Radio Television of Serbia), which featured the ULTRA microneedle technology in a segment of the documentary series, A Guide to the Future (Vodič kroz budućnost). The full-length documentary is available on YouTube and is mostly in Serbian (Wing and I speak about the ULTRA microneedle technology in English). The segment about our ULTRA microneedle technology starts around the 17-minute mark.
Thanks to RTS and their crew for their invaluable time and efforts in creating this fantastic coverage.